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Summary The use of molecular biological methodologies has provided a greater understanding of the
cytotoxic effects ofcisplatin and the underlying mechanisms of tumour cell resistance. Resistance to cisplatin is
often multifocal with plasma membrane, cytosolic and nuclear components. Cisplatin-DNA adducts appear to
be recognised by specific damage recognition proteins. Proteins associated with the transport of platinum
through plasma membranes and genes associated with cisplatin resistance appear to be close to being
elucidated. Current Phase I and Phase II clinical trials with platinum-containing complexes largely focus on
the 1,2 diaminocyclohexane (DACH) carrier ligand, the dicarboxylatocyclobutane leaving group and com-
plexes which circumvent cisplatin resistance in murine leukaemia models. At present, the trials are at too early
a stage to allow comment on their clinical utility and, consequently, the relevance of the murine leukaemia-
based preclinical observations. On the horizon, orally active platinum (IV) ammine/amine dicarboxylate
dichloride coordination complexes with preclinical toxicological profiles similar to carboplatin should enter
clinical trial in the next year.
The antitumour properties of cisplatin [cis diamminedichloro
platinum (II)] were discovered over 20 years ago. The first
cancer patient received the drug in 1971. Since then, platinum
drug development has proceeded in two broad directions
aimed at either modulation of the toxic side effects of the
parent drug (particularly nephrotoxicity) or circumvention of
cisplatin resistance (both intrinsic and acquired) in tumours.
To date, despite numerous synthetic chemistry initiatives,
only one additional platinum complex, carboplatin [Parap-
latin, cis diammine, 1,1-cyclobutane dicarboxylato platinum
(II)] has received worldwide registration and acceptance.
At the sixth quadrennial international symposium on
Platinum and Other Metal Coordination Compounds in
Cancer Chemotherapy held at San Diego, California from
23-26th January 1991, over 50 invited lectures and over 250
posters were presented. We have attempted to summarise
recent advances in the field presented at this symposium
under three broad headings: synthetic chemistry, biochemical
and molecular pharmacology and clinical trials.
Synthetic chemistry
A major initiative by the Johnson Matthey Technology Centre
in collaboration with the Institute of Cancer Research and
Bristol-Myers Squibb is aimed at designing an orally active
platinum drug. Towards this end, Giandomenico (Johnson
Matthey, West Chester, Philadelphia, USA) reported the
preparation of a series ofplatinum (IV) ammine/amine dicar-
boxylate dichlorides. A general structure is shown in Figure 1.
Harrap (Institute of Cancer Research, Sutton, Surrey, UK)
showed that this class of agent displayed potent in vitro
antitumour activity, particularly against intrinsically cisplatin
resistant human ovarian carcinoma cell lines. Moreover, in
vivo, after oral administration, the complexes showed good
absorption and marked antitumour activity against both a
murine plasmacytoma (ADJ/PC6) and cisplatin-sensitive
ovarian xenografts. Mechanistic experiments revealed that
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Figure 1 General structure of orally active Pt(IV) dicarboxylate.
the platinum (IV) dicarboxylates are readily reduced to
platinum (II) species by biologically relevant reductants such
as ascorbate. Their preclinical toxicological profiles were
shown by Harrap to be carboplatin-like rather than cisplatin-
like (myelosuppression being dose-limiting).
As cisplatin and carboplatin form essentially the same
spectrum of adducts on DNA, numerous synthetic chemistry
programmes have been aimed at the design of complexes
capable of forming a different spectrum of adducts. Some of
these attempts are shown in Figure 2. Farrell (University of
Vermont, Burlington, Vermont, USA) described the synthesis
and biological properties of several bis and trans platinum
complexes (1 and 2, Figure 2). Some of these complexes
displayed interesting in vitro cytotoxicity profiles, showing an
altered spectrum of activity when compared to cisplatin.
Complexes such as 2 are intriguing as historically trans
platinum compounds have been relatively inactive. It was
suggested that DNA mono alkylation followed by inter-
calative interaction of the aromatic amine ligands may con-
tribute to the compounds cytotoxicity.
Hollis (Englehard Corporation, Edison, New Jersey, USA)
described a series of cationic platinum-triamine complexes
(3), where several demonstrated activity against murine S180,
P388 and L1210 tumours in vivo. The authors suggested that
cytotoxicity again may be due in part to the formation of a
DNA monoadduct followed by binding of the cis aromatic
amine ligand (i.e. pyridine) in the minor groove. It is interest-
ing to note that the trans pyridine complex (2) and the
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Figure 2 Novel classes of platinum complex.
triamine (3) may share common fundamental events leading
to their cytotoxic effect.
The preparation and preclinical studies on D-19466 (4),
which contains a seven-membered Pt-1,2 bis(methylamino)
cyclobutane chelate, was reported by Katscher (ASTA
Pharma, Frankfurt, Germany). The basic framework of the
unique amino ligand was assembled via thermal or
photochemical head-to-head dimerisation of acrylonitrile.
The complex was shown to be active against a variety of in
vivo murine tumour models, and human xenografts, and it
also displayed in vitro activity against cisplatin-resistant P388.
Several platinum (II) complexes of fluorocarbon-substituted
organoamides which bear little structural resemblance to
cisplatin were reported by Deacon (Monash University
Clayton, Victoria, Australia). The complexes were prepared
by a novel platinum-mediated decarboxylation reaction.
Compound 5, where L equals pyridine, displayed in vitro
activity against both cisplatin sensitive and resistant L1210
and P388 cell lines. Although the compound's activity was
maintained in vivo against cisplatin-sensitive P388 leukaemia
in mice, they had little effect on the resistant tumours.
An unusual series of platinum (IV) metallocyclobutanes
with in vitro activity against Lewis Lung and B16 melanoma
tumour cell lines was reported by Jennings (Montana State
University, Bozeman, Montana, USA). In search of agents
with increased efficacy against mammary and prostate
cancers, a number of attempts have been made in recent
years to prepare oestrogen receptor (ER) affinic cytotoxic
platinum complexes. Schonenberger (University of Regens-
berg, Regensberg, Germany) described the preparation and
activity of several ring-substituted [1,2 bis(4-hydroxy-
phenyl)ethylenediamine Pt(II) dichloride] complexes which
showed antitumour activity against ER positive tumours
such as the MTX mammary carcinoma and R3327 Dunning
prostate cancer. Another series of ER targeted dichloro-
platinum (II) complexes with an ER affinic 5-hydroxy-2 (4-
hydroxyphenyl) indole moiety were described by von Angerer
(University of Regensberg, Regensberg, Germany). The com-
pounds were inactive against ER negative MDA-MB 231
mammary tumour cells but active against the ER positive
variant.
There were very few reports in the area of non-platinum
metal complexes. Ware (University of Auckland, Auckland,
New Zealand) described a series of Co (III) complexes
designed to release a cytotoxic alkylating agent upon
metabolic reduction to Co (II) under hypoxic conditions.
Although the possibility exists for intramolecular N-
alkylation of the diamine mustards in these complexes upon
reduction to Co (II) (which would inactivate the alkylating
function) some hypoxia selective cytotoxicity was observed
against AA8 Chinese hamster fibroblasts. Several ruthenium
(II) DMSO complexes containing a nitrogen heterocyclic
ligand were reported by Alessio (University of Trieste,
Trieste, Italy). The anionic imidazole derivative, Na(t-
Ru(DMSO)mCL4) in particular, was active against P388
leukaemia (T/C = 170) and showed some activity against
platinum resistant P388 and M5076 reticulum sarcoma.
In addition to synthetic efforts, our understanding of the
solution structure of platinum-DNA adducts has been in-
creased. Patel (Columbia University, New York, USA) for
example, used 2D nuclear magnetic resonance COESY and
NOESY techniques to structurally characterise a complimen-
tary dodecanucleotide duplex which contained a cis
Pt(NH3)2-G-G lesion in the centre. More studies on the
structural nature of Pt-DNA adducts were described by Lip-
pard (Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA). These included the use of site
specifically modified DNA oligonucleotides to incorporate cis
GG, AG, GTG and trans GTG adducts into duplex DNA
via amplification techniques. DNA bending determinations
showed that the cis adducts induced bends of between 320
and 350. In addition, it was found that the cis GG and AG
adducts both unwind DNA by 130, a value which correlates
with repair by the bacterial (A)BC exinuclease enzyme com-
plex.
Biochemical and molecular pharmacology
There is a large body of evidence showing that cisplatin
exerts its cytotoxic effects through binding to DNA, princi-
pally through the formation ofguanine-guanine and adenine-
guanine intra- and, to a much lesser extent, inter-strand
crosslinks. Cellular resistance to cisplatin may occur via
mechanisms prior to DNA binding (i.e. at the plasma mem-
brane or cytoplasmic level) or at the level of DNA itself
(Figure 3).
Several presentations addressed the biochemistry ofcisplatin
transport through plasma membranes. Andrews (Georgetown
University, Rockville, Maryland, USA) studied cisplatin
accumulation effects in an acquired resistant human ovarian
carcinoma cell line (2008) where reduced accumulation plays
a role in the mechanism of resistance. Resistant cells
appeared to possess alterations in their ion transport systems
so as to increase their membrane potential as a means of
reducing cisplatin accumulation. Why membrane potential
should affect the transport of a neutral molecule such as
cisplatin is at present unclear. Other groups have, for the first
time, implicated specific plasma membrane proteins with790 M.J. MCKEAGE et al.
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Figure 3 Mechanisms of cellular resistance to platinum drugs.
cisplatin resistance. Ling (Ontario Cancer Institute, Toronto,
Ontario, Canada) described the over-expression of a 200
kilodalton membrane glycoprotein (CPR200) in a cisplatin
resistant murine lymphoma cell line. As yet, the glycoprotein
has not been fully characterised. Fojo (National Cancer Ins-
titute, Bethesda, Maryland, USA) suggested a possible rela-
tionship between a 55 kD protein localised to the high speed
membrane fraction and acquired resistance to cisplatin in
resistant sublines of the A2780 human ovarian carcinoma.
Levels of protein were reduced in cisplatin resistant lines
associated with decreased accumulation.
The possible role of the intracellular thiol-rich proteins,
metallothioneins, in cisplatin resistance was presented by
Lazo (University of Pittsburgh, Pittsburgh, Philadelphia,
USA). At least some human tumour cells with acquired
resistance to cisplatin exhibit an increased level of metal-
lothionein (particularly isoform IIA), as measured at both the
mRNA and protein level.
At the nuclear level, much knowledge has recently accrued
relating to the interaction of cisplatin with DNA and the
subsequent repair of platinum-DNA adducts. Rather than
using techniques such as alkaline elution which measures
repair of interstrand crosslinks over the entire genome, Bohr
(National Cancer Institute, Bethesda, Maryland, USA) des-
cribed elegant methodology based on molecular biological
techniques to compare the repair of both intra- and inter-
strand crosslinks in specific actively transcribing genes [di-
hydrofolate reductase (DHRF), multidrug resistance (mdrl)
and c-myc] vs non-coding fragments of DNA. Intrastrand
adducts were detected by bacterial (A)BC exinuclease enzyme
digestion and interstrand crosslinks via a denaturation-
renaturation procedure followed by gel electrophoresis and
Southern hybridisation. He showed, using two cisplatin sen-
sitive and acquired-resistant pairs of human ovarian cancer
cell lines (A2780/DDP and 2008/DDP) that removal of intra-
strand adducts was similar in both the parent and resistant
lines. Removal of interstrand crosslinks, however, was much
faster from specific genes in the resistant lines as compared to
the sensitive counterparts. Interestingly, alkaline elution
revealed no differences in removal. Thus cisplatin resistance
can be associated with an increase in gene-specific DNA
repair without marked changes in the overall genome repair.
Instead of using (A)BC exinuclease, Eastman (Dartmouth
School of Medicine, Hanover, New Hampshire, USA) de-
scribed a polymerase chain reaction-based method of similar
sensitivity to detect cisplatin adducts in DNA.
Using clinical samples from patients receiving platinum-
based chemotherapy, Reed (National Cancer Institute,
Bethesda, Maryland, USA) assessed RNA for the human
DNA excision repair gene ERCC1. High levels of expression
in fresh tumour tissue appeared directly related to clinical
resistance (P = 0.051). In one patient where levels in tumour
tissue and peripheral blood were measured before treatment
with carboplatin and after the development of clinical resist-
ance, ERCC1 expression increased 10-fold in the tumour and
5-fold in white blood cells. The group suggested that ERCC1
expression may be an important marker for clinically
relevant DNA repair capability. Wood (Imperial Cancer
Research Fund, Potters Bar, Hertfordshire, UK) described
an assay which measures the repair of cisplatin-damaged
DNA in vitro by human cell extracts. Preliminary attempts to
apply the assay to investigate DNA repair capacity in human
tumour biopsies were described by Harris (Churchill Hos-
pital, Oxford, UK). Further evidence for the involvement of
DNA repair capacity in cisplatin resistance was described by
Harrap (Institute of Cancer Research, Sutton, Surrey, UK)
using a cisplatin-hypersensitive human testicular
nonseminomatous germ cell line and a 6.5-fold acquired
resistant variant, the removal of total platinum bound to
DNA being enhanced in the resistant line.
The role of oncogene expression and signal transduction
pathway regulation on cisplatin sensitivity was addressed by
several groups. Sklar (University of Michigan, Ann Arbor,
Michigan, USA) described the modulation of resistance to
cisplatin in mouse NIH3T3 fibroblasts by c-Ha-ras and c-myc
oncogenes. Ras oncogene transfection significantly increased
resistance to cisplatin (4.5-fold to 10-fold differences in IC50
values) as well as to ionising radiation. Using cells containing
amplified c-myc sequences in either sense or antisense orien-
tations, the group showed that cisplatin resistance correlated
with c-myc levels; induction ofc-myc increased cisplatin resis-
tance by about 3-fold. Howell (UCSD, La Jolla, California,
USA) showed that activiation of either the protein kinase A
or protein kinase C pathways enhanced sensitivity of human
ovarian 2008 cells to cisplatin by 2- to 3-fold. In contrast,
and in accordance with the Sklar studies, c-Ha-ras oncogene
over-expression in NIH3T3 cells (greater than 10-fold increase
in p2l'r expression after 24 h) reduced cisplatin sensitivity by
8.2-fold. Scanlon (City of Hope National Medical Center,
Duarte, California, USA) described studies suggesting a role
for the c-fos oncogene in cisplatin resistance using a fos
ribozyme (catalytic RNA) expressed in the A2780 human
ovarian carcinoma cell line. However, not all studies showed
such effects. Kerr (University of Glasgow, Glasgow, UK)
transfected H-ras and c-myc into mink lung epithelial cells
and showed no alterations in sensitivity to cisplatin.
Essigmann (Massachusetts Institute of Technology, Camb-
ridge, Massachusetts, USA) described further studies on the
recently discovered protein present in human and rodent cells
that specifically binds to DNA modified with cisplatin but
does not bind to inactive platinum agents (e.g. transplatin).
The protein, of an apparent molecular weight of 91,000,
maps to chromosome llq and binds specifically to the 1,2-
intrastrand G-G and A-G adducts. Although expression has
been found in many different tissues it did not correlate with
cisplatin resistance in a number of human, hamster and
mouse cell lines. Other such damage recognition proteins,
which appear from preliminary experiments to be overexp-
ressed in cisplatin resistant cell lines, were described by
Brown (University of Glasgow, Glasgow, UK) and Chao
(Chang Gung Medical College, Taoyman, Taiwan).
There was one report of the isolation of a gene associated
with cisplatin resistance (Enns, UCSD, La Jolla, California,
USA). Libraries were made from a human ovarian cell line
(2008) and a 10-fold cisplatin resistant variant (C13) and
cotransfected with PSP2-neo into Chinese hamster ovary
cells. Human inserts from seven cisplatin-resistant clones
were recovered using polymerase chain reaction
methodology. All of the inserts were of the same size; two
were sequenced revealing a sequence corresponding closely to
the human mitochondrial heat shock protein 60, P1. To date,
however, the gene has not been transfected back into thePLATINUM COMPLEXES IN CANCER CHEMOTHERAPY 791
parent line and consequently its biological relevance to cisp-
latin resistance is uncertain.
Clinical trials
Early phase clinical trials of eight new antitumour platinum
complexes were reported. Their chemical structures are shown
in Figure 4.
Christian (National Cancer Institute, Bethesda, Maryland,
USA) and O'Rourke (Brooke Army Medical Center, Houston,
Texas, USA) presented preliminary reports of Phase I studies
of ormaplatin (tetrachloro(l-trans)1,2-diaminocyclohexane
platinum (IV)). This DACH compound with pharmaceutical
properties suitable for intravenous formulation lacks cross
resistance against acquired cisplatin resistant murine
leukaemias and has a preclinical antitumour spectrum other-
wise similar to cisplatin. Maximum tolerated doses and dose
limiting toxicities have not yet been reached, but emesis has
been encountered at the lowest dose levels.
The development of oxaliplatin (1,2-diaminocyclohexane(l-
trans)oxalatoplatinum (II)) was reviewed by Misset (Hospital
Paul-Brousse, Villejuif, France). This agent has activity
against cisplatin resistant L1210 and less experimental
nephrotoxicity and myelosuppression than cisplatin. Phase I
studies ofintravenous bolus dose and continuous intravenous
infusion oxaliplatin found emesis and cumulative neurotoxi-
city to be dose limiting. The neurotoxicity was characterised
by progressive sensory neuropathy, acute parasthesiae and
electrophysiological abnormalities. Phase II studies are on-
going in France.
Perez-Solar (MD Anderson Cancer Center, Houston, Texas,
USA) reviewed the development of cis-bis-neodecanoato-
trans-R,R-1,2-diaminocyclohexane platinum (II) (NDDP), a
platinum complex with high liposomal entrapment efficiency
and stability. In liposomal formulation (L-NDDP) this agent
has partial non-cross resistance in cisplatin resistant L1210,
superior activity to cisplatin in experimental hepatic meta-
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Figure 4 Platinum complexes currently in Phase I/II development.
stases, and less nephrotoxicity than cisplatin in mice. A phase
I study of intravenous L-NDDP found a maximum tolerated
dose of 312.5 mg m-2 and dose limiting myelosuppresion. No
nephrotoxicity or neurotoxicity was encountered, but emesis
occurred in most patients despite prophylactic antiemetics. A
Phase I study of L-NDDP administered by hepatic arterial
infusion is ongoing.
Zeniplatin (2,-bis(aminomethyl)-1,3-propanediol-N,N' (1,1-
cyclobutanedicarboxylato(2-)-0,0'platinum(I)) and enloplatin
((sp-4-2)-(l,I-cyclobutanedicarboxylato(2-)-0,0')tetrahydro-4H
-pyran-4,4methamine N,N) platinum(II) are being developed
by the American Cyanamid Company. Both are highly water
soluble complexes with experimental in vivo antitumour
activity broadly comparable to cisplatin and carboplatin, with
the exception of enloplatin's non-cross resistance against cis-
platin resistant L1210. Both compounds appear less nephro-
toxic than cisplatin on the basis of BUN elevations in rats.
Ceulemans (Univeristy Catholique de Louvain, Brussels, Bel-
gium) reported a Phase I study of enloplatin in which neutro-
penia and nephrotoxicity were dose limiting at the maximum
tolerated dose of 1227 mg m2. De Valeriola (Institut Jules
Bordet, Brussels, Belgium and University of Maryland Cancer
Center, Baltimore, Maryland, USA) reported a Phase I study
of zeniplatin and the maximum tolerated dose was 145 mg
m 2, with dose limiting leukopenia. Phase II studies of zeni-
platin were presented by Jones (Royal Marsden Hospital,
Sutton, Surrey, UK) and Aamdal (EORTC Early Clinical
Trials Group). This agent is active in non-small lung cancer
and malignant melanoma, though nephrotoxicity appears to be
a major limitation.
Majima (Institute of Microbiol Chemistry, Tokyo, Japan)
reviewed the Japanese development of three platinum com-
plexes, 254-S (cisdiammine(glycolato)platinum II), Cl 973
or NK 121 ((SR-4-3-IR)-[1,1-cyclobutanedicarboxylato(2-)] (2
methyl-1,4-butanediamine-N,N')platinum II), and DWA2114R
(2 - aminomethyl - pyrrolidine (1,1 -cyclobutanedicarboxylato)
platinum II). All three have antitumour activity and low neph-
rotoxic potential in murine models, activity against human
tumour xenografts, and partial or complete non-cross resis-
tance against cisplatin resistant murine K562 leukaemia. In
Phase I studies, including that presented by O'Dwyer (Fox
Chase Cancer Center, Philadelphia, Pennsylvania, USA), leu-
kopenia or thrombocytopenia were the dose limiting toxicities
in all instances, except in the case of continuous intravenous
infusion ofDWA2114R, when emesis and diarrhoea were dose
limiting. Phase II studies are ongoing in Japan. Hirabayashi
(National Hospital Fukuyama, Fukuyama, Japan) reported
encouraging activity of 254-S in combination with peplomycin
and ifosfamide in advanced cervical cancer.
After the clinical evaluation of these eight new platinum
complexes have been completed little doubt should exist as to
the utility of the cisplatin resistant murine leukaemias and the
1,2-diaminocyclohexane ligand, as models of and a strategy to
circumvent clinical cisplatin resistance, since seven ofthese new
complexes lack cross resistance to cisplatin resistant murine
leukaemias, and three are 1,2-diaminocyclohexane derivatives.
The dicarboxylatocyclobutane substituent is a feature of four
platinum complexes in clinical development. Two of these
agents are associated with significant clinical nephrotoxicity
which is surprising in view ofthe previously described relation-
ship between leaving group stability and kidney damage. Some
of the new compounds cause major non-haematological toxici-
ties, e.g. neurotoxicity, nephrotoxicity and severe emesis, which
may limit their clinical application unless unique activity is
demonstrated. Interestingly, some of the new platinum com-
plexes are unlike carboplatin in that their myelosuppression
predominants against the white cell lineage rather than
platelets.
Taxol, an alkaloid extracted from the Pacific Yew (Taxus
brevifolia) is active in advanced and cisplatin refractory
ovarian cancer, and has major toxicities that are not shared
with cisplatin. The cytotoxicity of the taxol-cisplatin combina-
tion is sequence dependent, with taxol followed by cisplatin
treatment sequence having the highest in vitro activity. A phase
I study of this combination was reported by Rowinsky (Johns792 M.J. MCKEAGE et al.
Hopkins Oncology Center, Baltimore, Maryland, USA). Neut-
ropoenia was dose limiting and sequence dependent, being
more severe with cisplatin preceding taxol. This treatment
sequence was also associated with reduced taxol clearance.
Other toxicities include emesis, alopecia and, in four patients,
ventricular tachycardia. The recommendations for Phase II
studies are the taxol before cisplatin treatment sequence and
cisplatin/taxol doses of 75-135 mg m-2 with further taxol
escalation iftolerable. Results ofthese studies are awaited with
interest.
The development of ORG 2766, a neurotrophic ACTH
analogue devoid of adrenocorticotrophic properties was up-
dated by Hamers (Rudolf Magnus Institute, Utrecht, The
Netherlands). This peptide's efficacy in the prophylaxis and
treatment of cisplatin-induced neuropathy was first demon-
strated in the rat model and its preventive action has been
confirmed in ovarian cancer patients receiving cisplatin, in
whom very few side effects were apparent. Experiments
demonstrating the efficacy of ORG2766 during high dose
cisplatin treatment were presented.
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